ML277 specifically enhances the fully activated open state of KCNQ1 by modulating VSD-pore coupling

Panpan Hou, Jingyi Shi, Kelli McFarland White, Yuan Gao, Jianmin CuieLife 2019 · DOI

TL;DR

This study reveals that the small molecule ML277 specifically enhances the "fully activated" (AO) open state of the KCNQ1 potassium channel, rather than the "intermediate" (IO) open state. This selective modulation is achieved by influencing the electromechanical (E-M) coupling between the voltage-sensing domain (VSD) and the pore, offering a new avenue for treating Long QT Syndrome (LQTS).

What Problem Does This Paper Address?

The KCNQ1 potassium channel is crucial for regulating heart rhythm, and its dysfunction is linked to life-threatening arrhythmias like Long QT Syndrome (LQTS). KCNQ1 exhibits a complex gating mechanism, opening into two distinct states: an intermediate-open (IO) state and a fully activated-open (AO) state. While the AO state is considered more physiologically relevant, especially when KCNQ1 is complexed with KCNE1 in the heart (forming I<sub>Ks</sub> currents), understanding how to selectively modulate these states has been challenging. Existing KCNQ1 activators often lack specificity, affecting other ion channels and potentially leading to side effects. This paper aims to elucidate the precise mechanism by which ML277, a known KCNQ1 activator, exerts its effects, specifically investigating whether it targets one or both open states and how it influences the VSD-pore coupling.

Methods

The researchers employed a multi-faceted approach:

  • Electrophysiology in Xenopus Oocytes: Whole-cell currents from KCNQ1 and KCNQ1+KCNE1 channels were recorded using two-electrode voltage clamp (TEVC) to assess the effects of ML277 on current amplitude, kinetics, and voltage dependence.
  • Mutant Channel Analysis: Specific KCNQ1 mutants were used to isolate either the IO or AO open states. This allowed the researchers to determine if ML277's effects were specific to a particular open state.
  • Voltage-Clamp Fluorometry (VCF): This technique was used to monitor the movement of the voltage-sensing domain (VSD) in pseudo-wild-type KCNQ1 channels, allowing researchers to decouple VSD activation from pore opening and investigate the VSD-pore coupling.
  • Ion Permeation Assays: Experiments using different external solutions (potassium vs. rubidium) were conducted to probe changes in ion selectivity, which can reflect alterations in the pore's open state.
  • Kinetic Modeling: A simplified five-state Markov model was developed and parameterized to simulate the observed effects of ML277 and test hypotheses about its mechanism of action.

Datasets

Not discussed in the paper. The study relies on experimental data generated from Xenopus oocytes expressing KCNQ1 and KCNQ1+KCNE1 channels.

Key Insights and Ideas

  • ML277 is an AO-state specific enhancer: This is the central finding. ML277 doesn't just boost overall channel activity; it specifically amplifies the current flowing through the AO state, leaving the IO state largely unaffected. This is a significant step towards understanding state-dependent channel modulation.
  • VSD-Pore Coupling is the Target: The data strongly suggest that ML277 doesn't alter the fundamental voltage-sensing domain (VSD) activation itself. Instead, it appears to enhance the "electromechanical coupling" – the process by which the VSD's movement translates into pore opening – specifically when the VSD is in its fully activated (AC) state, leading to the AO state.
  • Distinct E-M Coupling Mechanisms: The study reinforces the idea that KCNQ1 has different E-M coupling mechanisms for its IO and AO states. ML277's specificity points to a unique interaction site or pathway that is only engaged or modulated when the VSD is in the activated conformation.
  • Potential for Targeted LQTS Therapy: By selectively enhancing the AO state, which is crucial for I<sub>Ks</sub> currents in the heart, ML277 offers a promising strategy for developing new treatments for LQTS, potentially with fewer off-target effects than broader-acting channel modulators.

Key Results

  • ML277 significantly increased KCNQ1 current amplitudes, primarily by prolonging the slow component of activation (associated with the AO state), while leaving the fast component (IO state) largely unchanged.
  • The drug caused a slight rightward shift in the KCNQ1 channel's conductance-voltage (G-V) relationship, consistent with an increased contribution of the AO state (which has a right-shifted G-V compared to the IO state).
  • ML277 slowed down the inactivation process (hook current in tail currents), which is linked to the AO state, further supporting its selective action on this state.
  • The Rb+/K+ permeability ratio of KCNQ1 channels was significantly decreased by ML277, bringing it closer to that of I<sub>Ks</sub> channels, which are AO-dominant.
  • ML277 specifically enhanced currents from mutant KCNQ1 channels that were engineered to open only in the AO state (E1R/R4E and F351A), while having minimal effect on mutants that open only in the IO state (E1R/R2E and S338F).
  • VCF experiments showed that ML277 did not alter VSD activation kinetics but did lead to a right-shifted G-V relationship, supporting the idea of enhanced E-M coupling rather than VSD changes.
  • Kinetic modeling successfully recapitulated ML277's effects by reducing the rates of exiting the AO state, suggesting ML277 stabilizes the AO conformation.

Limitations and Future Work

  • Model Simplification: The kinetic model used is a simplified five-state model and cannot fully reproduce all observed effects, such as the slowing of activation and deactivation kinetics. The authors suggest that ML277 might have an additional effect on AO state gating kinetics that the model doesn't capture.
  • In Vitro vs. In Vivo: The study was conducted in Xenopus oocytes. While this is a standard model, future work could explore ML277's effects in more complex cellular and in vivo systems.
  • ML277 Binding Site: While previous studies suggest ML277 binds intracellularly, further investigation into the precise binding site and its interaction with specific residues involved in AO state E-M coupling would be valuable.
  • KCNE1 Saturation: The study notes that ML277's effect is diminished with saturated KCNE1 binding. Understanding how ML277 interacts with KCNE1-bound KCNQ1 channels in native I<sub>Ks</sub> currents is crucial for its therapeutic potential.
  • Therapeutic Development: The authors highlight the potential for ML277 as an anti-LQTS drug, but further pre-clinical and clinical studies would be necessary to validate this.

Summary updated

Abstract

Upon membrane depolarization, the KCNQ1 potassium channel opens at the intermediate (IO) and activated (AO) states of the stepwise voltage-sensing domain (VSD) activation. In the heart, KCNQ1 associates with KCNE1 subunits to form I<sub>Ks</sub> channels that regulate heart rhythm. KCNE1 suppresses the IO state so that the I<sub>Ks</sub> channel opens only to the AO state. Here, we tested modulations of human KCNQ1 channels by an activator ML277 in <i>Xenopus</i> oocytes. It exclusively changes the pore opening properties of the AO state without altering the IO state, but does not affect VSD activation. These observations support a distinctive mechanism responsible for the VSD-pore coupling at the AO state that is sensitive to ML277 modulation. ML277 provides insights and a tool to investigate the gating mechanism of KCNQ1 channels, and our study reveals a new strategy for treating long QT syndrome by specifically enhancing the AO state of native I<sub>Ks</sub> currents.
BibTeX
@inproceedings{hou2019ml,
  author = {Panpan Hou and Jingyi Shi and Kelli McFarland White and Yuan Gao and Jianmin Cui},
  title = {{ML277 specifically enhances the fully activated open state of KCNQ1 by modulating VSD-pore coupling}},
  booktitle = {eLife},
  year = {2019},
  doi = {10.7554/elife.48576},
}
Figure